ClinicalTrials.gg
CompletedNCT03882281CMLUpdated Jan 22, 2020

Pharmacokinetics Profiles of HQP1351 Under Fasting and High-fat Meals in Patients With Chronic Myeloid Leukemia

A Phase 1 interventional study of HQP1351 in Chronic Myeloid Leukemia, Chronic Phase, sponsored by Ascentage Pharma Group Inc.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2020-01-22.

Sponsored by Ascentage Pharma Group Inc. (part of Ascentage Pharma Group International) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Leukemia, Myeloid, Chronic-Phase with a site in China — 3 open to participants now, 4 under way, 1 of them phase 3. Leukemia, Myeloid, Chronic-Phase · China.

Enrollment
13th of 13
12 · median 108
Started
2019
with 3 others
Phase 1
2 of 13
1 open now
Registered
4th of 13
by date
Lead sponsor
3 of 13
Ascentage Pharma Group Inc.

Among the 13 studies in Leukemia, Myeloid, Chronic-Phase with a site in China, this one is the 13th largest by enrollment, is one of 4 that started in 2019, is one of 2 in phase 1, and was the 4th registered.

Leukemia, Myeloid, Chronic-Phase

439 studies on the registry are indexed under Leukemia, Myeloid, Chronic-Phase; 27 are open to participants now.

Browse Leukemia, Myeloid, Chronic-Phase studies →

Open to participants now

3 of the 13 studies in Leukemia, Myeloid, Chronic-Phase with a site in China are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 20 Leukemia, Myeloid, Chronic-Phase studies recruiting now, 13 (65%) set no upper age limit and 5 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Leukemia, Myeloid, Chronic-Phase with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the pharmacokinetics of HQP1351 in participants with resistant chronic myeloid leukemia (CML) in chronic phase (CP) after high-fat and fasting meals separately(Selection of high-fat meal spectrum:《The Food - Effect Bioavailability and Fed Bioequivalence Studies》high fat diet should be 800-1000 kcal heat.).

Read the detailed description

The drug being test in this study is HQP1351,the study will characterize the pharmacokinetics of HQP1351 in participants with resistant chronic myeloid leukemia(CML)in chronic phase(CP)after high-fat meal and fasting meal separately at a dose of 30mg,single-dose. The study will enroll 12 subjects totally and be randomly divided into 2 groups(A group and B group). Every group will have 6 subjects. The experiment is divided into two periods,in period 1, subjects in the group A will be given HQP1351 30mg after fasting meal,and the group B will be given HQP1351 30mg after 30 minutes of high-fat meal. Then after a seven-day of cleaning time the two groups of subjects took the drug interchangeably in the period 2.

03

Conditions studied

  • Chronic Myeloid Leukemia, Chronic Phase

Keywords

  • Chronic Myeloid Leukemia, Chronic Phase
  • HQP1351
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or non-pregnant, non-lactating female patients age 18-55 years old.
  2. CML Patients in CP with Ph-positive or BCR/ABL-positive.
  3. Previously treated with and or developed resistance / intolerance to second generation tyrosine kinase inhibitors (TKIs) (dasatinib,nilotinib)or,been identified to have the T315I mutation at any time during treatment.
  4. Ability to understand and willingness to sign a written form. The consent form must be signed by the patient prior to any study-specific procedures.
  5. (ECOG) Performance Status ≤ 2.
  6. Predicted of ≥3 months.
  7. Organ function as indicated by the following laboratory indicators must be met:

    • ≥8.0g/dL.
    • White blood cell count ≥ 3.0×10\^9/L, ≥ 1.5 x 10\^9/L.
    • count ≥ 75×10\^9/L.
    • Serum creatinine ≤ 1.5× (ULN) or 24 hours calculated ≥ 50ml/min when serum creatinine >1.5×ULN.
    • Serum albumin≥ 3.0 g/dL.
    • Total ≤ 1.5 x ULN.
    • (AST) and Alanine aminotransferase (ALT) ≤ 2.5 x ULN of institution's normal range.
    • Lipase≤1.5×ULN, Amylase≤1.5×ULN.
    • (PT), activated partial thromboplastin time (APTT), INR≤1.5×ULN.
  8. Cardiac function index: (EF) > 50%.
  9. interval (QTc) interval on (ECG) evaluation: QTc≤450ms in males or ≤470ms in females.
  10. Willingness to use by a method that is deemed effective by the investigator by both males and female patients of child bearing potential and their partners throughout the treatment period and for at least 120 days following the last dose of study drug.
  11. Willingness and ability to comply with study procedures and follow-up examination.

Exclusion criteria

Exclusion Criteria:

  1. Received cytotoxic chemotherapy or radiotherapy within 28 days, interferon or cytarabine within 14 days, any therapy within 14 days prior to the first dose of study drug, or have not recovered (> grade 1 by v 4.03) from adverse events (AEs ) (except alopecia) due to agents previously administered.
  2. Require concurrent treatment with drugs that may have interactions with the study drug.
  3. Have previously been treated with ponatinib (or drugs of similar composition).
  4. Absorption disorder syndrome or other diseases affecting oral drug absorption.
  5. Have any history of heart or vascular disease, such as hypertension (systolic blood pressure > 140 mmHg and/or diastolic blood pressure > 90mmHg), or take medications that are known to cause prolonged .
  6. Mean pulmonary artery pressure >25 mmHg.
  7. Have a history of serious cardiovascular diseases during the previous treatment of chronic myeloid leukemia with TKI.
  8. Underwent or allogeneic stem cell transplant.
  9. Abnormal coagulation function,or have a bleeding disorder within 3 months before first administration.
  10. Underwent major surgery (with the exception of minor surgical procedures, such as placement or bone marrow ) with 14 days prior to first dose of study drug.
  11. Require concurrent treatment with agents, other than prescribed for a short course of therapy.
  12. Have active nervous system (CNS) disease as evidence by cytology or pathology. In the absence of clinical CNS disease, lumbar puncture is not required.
  13. History of primary (cured for more than 5 years, completely resected superficial skin cancer other than melanoma, adequately treated in-situ cancer, or controlled prostate cancer will not be considered exclusionary).
  14. Active symptomatic infection.
  15. Known to be allergic to study drug ingredients or their analogues.
  16. Are pregnant or lactating or expecting pregnancy during the study program.
  17. Suffer from any condition or illness that, in the opinion of the Investigator or the sponsor, would compromise patient safety or interfere with the evaluation of the safety of the study drug.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    A group

    Subjects in the group A will be given HQP1351 after fasting meal on Day 1. Then after a seven-day of cleaning time, subjects in the group A will be given HQP1351 after 30 minutes of high-fat meal on Day 8.

    Drug: HQP1351

  • Experimental
    B group

    Subjects in the group B will be given HQP1351 after 30 minutes of high-fat meal on Day 1. Then after a seven-day of cleaning time, subjects in the group B will be given HQP1351 after fasting meal on Day 8.

    Drug: HQP1351

Interventions

  • Orally, single dose of 30mg on day 1 and day 8.

06

What researchers measure

Primary outcomes

  1. Area under the curve from the time of dosing to infinity [AUC(0-inf)]

    Area under the plasma concentration-time curve from time zero extrapolated to infinity time of HQP1351.

    Time frame: 1-5 days after every drug administration

  2. Area under the curve from the time of dosing to the last measurable concentration [AUC(0-last)]

    Area under the plasma concentration-time curve from time zero to the last measurable time point of HQP1351.

    Time frame: 1-5 days after every drug administration

  3. Percentage of AUC(0-inf)_obs due to extrapolation from the last measurable time point to infinity (AUC_%Extrap)

    Percentage of area under the concentration time curve from time zero extrapolated to infinite time obtained by extrapolation of HQP1351.

    Time frame: 1-5 days after every drug administration

  4. Maximum observed concentration (Cmax)

    Maximum observed plasma concentration of HQP1351.

    Time frame: 1-5 days after every drug administration

  5. Time of maximum observed concentration (Tmax)

    Time to maximum observed plasma concentration of HQP1351.

    Time frame: 1-5 days after every drug administration

  6. Terminal elimination half life (T1/2)

    Terminal elimination half life (T1/2) is defined as the duration until observation of half of the maximum concentration of HQP1351.

    Time frame: 1-5 days after every drug administration

  7. Total body clearance for extravascular administration (CL/F)

    Apparent clearance of HQP1351 following oral dosing. Clearance of a drug is a measure of rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose of HQP1351 (apparent oral clearance) is influenced by the fraction of dose absorbed.

    Time frame: 1-5 days after every drug administration

  8. Volume of distribution based on the terminal phase for extravascular administration (Vz/F)

    Apparent volume of distribution of HQP1351. Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution of HQP1351 after oral dose (Vz/F) is influenced by the fraction absorbed.

    Time frame: 1-5 days after every drug administration

Secondary outcomes

  1. Incidence of toxicity

    Incidence of toxicity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03

    Time frame: up to 12 days

07

Study locations

1 site
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Nov 2019, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2019
First posted
Mar 20, 2019
StartActual
Mar 25, 2019
Primary completionActual
Nov 16, 2019
CompletionActual
Nov 16, 2019
Last update
Jan 22, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 22, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03882281
Collaborators
HealthQuest Pharma Inc.
Responsible party
Sponsor
First posted
Mar 20, 2019
Start date
Mar 25, 2019
Primary completion
Nov 16, 2019
Completion
Nov 16, 2019
Last update
Jan 22, 2020

Study contacts

QIAN JIANG, Professor
principal investigator · Peking University People's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olverembatinib

Start the discussion